The Latest Breaking News from Edwards Lifesciences

Edwards Lifesciences (NYSE:EW) has outperformed the market over the past 20 years by 14.71% on an annualized basis producing an average annual return of 21.87%. Currently, Edwards Lifesciences has a market capitalization of $69.03 billion.

Edwards Lifesciences Corp (NYSE:EW) posted a Q1 adjusted EPS of $0.60, compared to $0.54 posted a year ago and beating the consensus of $0.57. Sales increased 10% to $1.34 billion (underlying 13%), beating the consensus of $1.31 billion. Transcatheter aortic valve replacement sales grew to $881 million, up 11%. Globally, the company's…

Growing demand from an aging population to track their diseases and increased focus on critical surgical procedures with lesser COVID-19 pressures on hospitals make the medical devices industry’s prospects bright. Moreover, the integration of emerging technologies and continued innovations should drive the industry’s growth. Therefore, prominent players in this space,…

Edwards Lifesciences (NYSE:EW) reported its Q1 earnings results on Tuesday, April 26, 2022 at 04:15 PM. Here's what investors need to know about the announcement.